Literature DB >> 22813937

Competing mortality contributes to excess mortality in patients with poor-risk lymph node-positive prostate cancer treated with radical prostatectomy.

Michael Froehner1, Albrecht Scholz, Rainer Koch, Oliver W Hakenberg, Gustavo B Baretton, Manfred P Wirth.   

Abstract

BACKGROUND: Factors predicting survival in men with lymph node-positive prostate cancer are still poorly defined. PATIENTS AND METHODS: 193 prostate cancer patients with histopathologically proven lymph node involvement with a median follow-up of 7.3 years were studied. 94% of patients received immediate hormonal therapy. Kaplan-Meier curves were calculated to evaluate overall survival rates and compared with the log-rank test. Cumulative disease-specific and competing mortality rates were calculated by competing risk analysis and compared with the Pepe-Mori test. Cox proportional hazard models were used to determine the independent significance of predictors of all-cause mortality.
RESULTS: Age (70 years or older vs. younger), Gleason score (8-10 vs. 7 or lower) and the number of involved nodes (3 or more vs. 1-2) were identified as independent predictors of all-cause mortality. When patients with 0-1 of these risk factors were compared with those with 2-3 risk factors, all-cause (rates after 10 years 21% vs. 71%, p < 0.0001), disease-specific (12 vs. 37%, p = 0.009) and competing mortality (9 vs. 33%, p = 0.02) differed significantly.
CONCLUSIONS: Some of the excess mortality in patients with poor-risk lymph node-positive prostate cancer may be attributed to increased competing mortality, possibly caused by an interaction between comorbid diseases and hormonally treated persistent or progressive prostate cancer.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 22813937     DOI: 10.1159/000339279

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  1 in total

1.  Effect of Gleason scores of lymph node metastases on prognosis of patients with prostate cancer.

Authors:  Kyungtae Ko; In Gab Jeong; Woo Suk Choi; Ju Hyun Lim; Ja Hee Suh; Ja Hyeon Ku; Yangsoon Park; Kyung Cheol Moon; Hyeon Hoe Kim; Choung-Soo Kim; Cheol Kwak
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.